These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

480 related articles for article (PubMed ID: 32625968)

  • 41. Preclinical hazard evaluation strategy for nanomedicines.
    Siegrist S; Cörek E; Detampel P; Sandström J; Wick P; Huwyler J
    Nanotoxicology; 2019 Feb; 13(1):73-99. PubMed ID: 30182784
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Methods of in vitro toxicology.
    Eisenbrand G; Pool-Zobel B; Baker V; Balls M; Blaauboer BJ; Boobis A; Carere A; Kevekordes S; Lhuguenot JC; Pieters R; Kleiner J
    Food Chem Toxicol; 2002; 40(2-3):193-236. PubMed ID: 11893398
    [TBL] [Abstract][Full Text] [Related]  

  • 43. How should the completeness and quality of curated nanomaterial data be evaluated?
    Marchese Robinson RL; Lynch I; Peijnenburg W; Rumble J; Klaessig F; Marquardt C; Rauscher H; Puzyn T; Purian R; Åberg C; Karcher S; Vriens H; Hoet P; Hoover MD; Hendren CO; Harper SL
    Nanoscale; 2016 May; 8(19):9919-43. PubMed ID: 27143028
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Strategy for genotoxicity testing: hazard identification and risk assessment in relation to in vitro testing.
    Thybaud V; Aardema M; Clements J; Dearfield K; Galloway S; Hayashi M; Jacobson-Kram D; Kirkland D; MacGregor JT; Marzin D; Ohyama W; Schuler M; Suzuki H; Zeiger E;
    Mutat Res; 2007 Feb; 627(1):41-58. PubMed ID: 17126066
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Scientific motivations and criteria to consider updating EFSA scientific assessments.
    ; Hardy A; Benford D; Halldorsson T; Jeger MJ; Knutsen KH; More S; Mortensen A; Naegeli H; Noteborn H; Ockleford C; Ricci A; Rychen G; Schlatter JR; Silano V; Solecki R; Turck D; Brock T; Chesson A; Karenlampi S; Lambre C; Sanz Y; Goumperis T; Kleiner J; Maurici D
    EFSA J; 2017 Mar; 15(3):e04737. PubMed ID: 32625443
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Threshold of toxicological concern for chemical substances present in the diet: a practical tool for assessing the need for toxicity testing.
    Kroes R; Galli C; Munro I; Schilter B; Tran L; Walker R; Würtzen G
    Food Chem Toxicol; 2000; 38(2-3):255-312. PubMed ID: 10717364
    [TBL] [Abstract][Full Text] [Related]  

  • 47. 2013 IFT International Food Nanoscience Conference: Proceedings.
    Newsome R
    Compr Rev Food Sci Food Saf; 2014 Mar; 13(2):190-228. PubMed ID: 33412649
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Nanotechnology: current uses and future applications in the food industry.
    Thiruvengadam M; Rajakumar G; Chung IM
    3 Biotech; 2018 Jan; 8(1):74. PubMed ID: 29354385
    [TBL] [Abstract][Full Text] [Related]  

  • 49. European Regulatory Framework and Safety Assessment of Food-Related Bioactive Compounds.
    Vettorazzi A; López de Cerain A; Sanz-Serrano J; Gil AG; Azqueta A
    Nutrients; 2020 Feb; 12(3):. PubMed ID: 32110982
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Identifying food proteins with allergenic potential: evolution of approaches to safety assessment and research to provide additional tools.
    Ladics GS; Selgrade MK
    Regul Toxicol Pharmacol; 2009 Aug; 54(3 Suppl):S2-6. PubMed ID: 19028539
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Safety and Toxicological Considerations of Nanomedicines: The Future Directions.
    Patel P; Shah J
    Curr Clin Pharmacol; 2017; 12(2):73-82. PubMed ID: 28486906
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Draft for internal testing Scientific Committee guidance on appraising and integrating evidence from epidemiological studies for use in EFSA's scientific assessments.
    ; More S; Bambidis V; Benford D; Bragard C; Hernandez-Jerez A; Bennekou SH; Koutsoumanis K; Machera K; Naegeli H; Nielsen SS; Schlatter JR; Schrenk D; Silano V; Turck D; Younes M; Fletcher T; Greiner M; Ntzani E; Pearce N; Vinceti M; Ciccolallo L; Georgiadis M; Gervelmeyer A; Halldorsson TI
    EFSA J; 2020 Aug; 18(8):e06221. PubMed ID: 32831946
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Guidance on the preparation and submission of an application for authorisation of a novel food in the context of Regulation (EU) 2015/2283 (Revision 1)
    ; Nutrition ; Nda A; Turck D; Bresson JL; Burlingame B; Dean T; Fairweather-Tait S; Heinonen M; Hirsch-Ernst KI; Mangelsdorf I; McArdle HJ; Naska A; Neuhäuser-Berthold M; Nowicka G; Pentieva K; Sanz Y; Siani A; Sjödin A; Stern M; Tomé D; Vinceti M; Willatts P; Engel KH; Marchelli R; Pöting A; Poulsen M; Salminen S; Schlatter J; Arcella D; Gelbmann W; de Sesmaisons-Lecarré A; Verhagen H; van Loveren H
    EFSA J; 2021 Mar; 19(3):e06555. PubMed ID: 33791039
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Nanomaterials in food and agriculture: An overview on their safety concerns and regulatory issues.
    Jain A; Ranjan S; Dasgupta N; Ramalingam C
    Crit Rev Food Sci Nutr; 2018 Jan; 58(2):297-317. PubMed ID: 27052385
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [International trend of guidance for nanomaterial risk assessment].
    Hirose A
    Yakugaku Zasshi; 2013; 133(2):175-80. PubMed ID: 23370509
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The carcinogenic potential of nanomaterials, their release from products and options for regulating them.
    Becker H; Herzberg F; Schulte A; Kolossa-Gehring M
    Int J Hyg Environ Health; 2011 Jun; 214(3):231-8. PubMed ID: 21168363
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Risks to human and animal health related to the presence of moniliformin in food and feed.
    ; Knutsen HK; Alexander J; Barregård L; Bignami M; Brüschweiler B; Ceccatelli S; Cottrill B; Dinovi M; Grasl-Kraupp B; Hogstrand C; Hoogenboom LR; Nebbia CS; Oswald IP; Petersen A; Rose M; Roudot AC; Schwerdtle T; Vleminckx C; Vollmer G; Wallace H; De Saeger S; Eriksen GS; Farmer P; Fremy JM; Gong YY; Meyer K; Naegeli H; Parent-Massin D; van Egmond H; Altieri A; Colombo P; Eskola M; van Manen M; Edler L
    EFSA J; 2018 Mar; 16(3):e05082. PubMed ID: 32625822
    [TBL] [Abstract][Full Text] [Related]  

  • 58. EFSA's framework for evidence-based scientific assessments: A case study on uncertainty analysis.
    Aiassa E; Merten C; Martino L
    ALTEX; 2022; 39(3):451–462. PubMed ID: 34185094
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A review and perspective of existing research on the release of nanomaterials from solid nanocomposites.
    Froggett SJ; Clancy SF; Boverhof DR; Canady RA
    Part Fibre Toxicol; 2014 Apr; 11():17. PubMed ID: 24708765
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Principles for characterizing the potential human health effects from exposure to nanomaterials: elements of a screening strategy.
    Oberdörster G; Maynard A; Donaldson K; Castranova V; Fitzpatrick J; Ausman K; Carter J; Karn B; Kreyling W; Lai D; Olin S; Monteiro-Riviere N; Warheit D; Yang H;
    Part Fibre Toxicol; 2005 Oct; 2():8. PubMed ID: 16209704
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.